The Story of Lithium: Discovery, Triumph, and Decline
ANCIENT ORIGINS — LITHIUM BEFORE LITHIUM
The Waters That Healed
Long before lithium was isolated as an element, its effects were experienced unknowingly:
- Ancient Greeks frequented natural springs in Ephesus, whose waters were extraordinarily rich in lithium. Physicians sent “lunatics” and “melancholics” to these springs, with reported benefit
- Soranus of Ephesus (1st–2nd century AD) recommended alkaline spring waters for mania and melancholia — almost certainly lithium-rich waters
- These healing springs were not understood chemically — they were attributed to divine favor or mysterious natural properties
CHAPTER 2: SCIENTIFIC BIRTH OF LITHIUM (1817)
The Discovery
1817 — Stockholm, Sweden
Laboratory of Jöns Jacob Berzelius
Assistant: Johan August Arfwedson
- Johan August Arfwedson, a young Swedish chemist working under the great Berzelius, was analyzing a mineral called petalite (a lithium aluminum silicate ore) found on the Swedish island of Utö
- He detected an unknown alkali metal that was distinctly lighter than sodium or potassium
- Berzelius named it “lithion” from the Greek lithos (λίθος) — stone — because, unlike sodium (found in plants) and potassium (found in ashes), lithium was discovered in rock
- Pure metallic lithium was first isolated by William Thomas Brande in 1821 via electrolysis
Early Chemical Properties Noted:
- Lightest metal on the periodic table (atomic number 3)
- Highly reactive with water
- Present in trace amounts in seawater, soil, and many foods
- Detected in meteorites and stellar atmospheres — a truly cosmic element
CHAPTER 3: 19TH CENTURY MEDICINE — LITHIUM’S FIRST MEDICAL LIFE
The Uric Acid Theory Era
1840s–1880s: Lithium as a "cure-all" for uric acid disorders
The dominant theory: A British physician, Alfred Baring Garrod, proposed in 1859 that gout, kidney stones, and a host of other ailments were caused by excess uric acid. Lithium urate was shown to be highly soluble in vitro — meaning lithium could theoretically dissolve uric acid crystals.
This launched lithium into mainstream medicine:
| Condition Treated | Rationale (at the time) |
|---|---|
| Gout | Dissolve uric acid crystals |
| Kidney stones | Uric acid theory |
| Rheumatism | Presumed uric acid involvement |
| Epilepsy | “Brain gout” hypothesis |
| Mania & Depression | “Cerebral gout” — excess uric acid in the brain |
Critical psychiatric connection: The “cerebral gout” hypothesis — that psychiatric disorders involved uric acid deposition in brain tissue — led physicians to prescribe lithium bromide for mania, depression, and epilepsy in the 1870s–1880s. This was largely accidental therapeutic reasoning that happened to point in the right direction.
Lithium Bromide in Psychiatry (1870s)
- William Hammond (Surgeon General of the US Army) used lithium bromide for mania in 1871, one of the earliest documented psychiatric uses
- Widely used in neurological practice across Europe
- Results were mixed — lithium bromide’s sedative effect (from the bromide component) confounded interpretation
- As the uric acid theory collapsed under scientific scrutiny, lithium fell from medical favor
CHAPTER 4: THE DARK INTERLUDE — LITHIUM’S DISGRACE (1940s)
A Near-Fatal Chapter
1949 — The Lithium Chloride Disaster
In the late 1940s, American cardiologists began using lithium chloride as a salt substitute for patients on sodium-restricted diets (heart failure, hypertension). It was sold commercially under names like “Westsal” and “Foodsal.”
The catastrophe:
- Lithium has a narrow therapeutic index — the difference between therapeutic and toxic doses is small
- Without any dosing guidance or blood level monitoring, patients consumed it freely
- Multiple cases of severe toxicity and death were reported throughout 1949
- The FDA issued a strong warning, and lithium chloride was pulled from shelves
- Lithium became synonymous with toxicity and death in American medical culture
This disaster would haunt lithium for decades and directly explain why American psychiatry was so slow to adopt it therapeutically — even after its efficacy was proven.
CHAPTER 5: THE GREAT REDISCOVERY — JOHN CADE (1949)
The Most Important Accidental Discovery in Psychiatric History
Bundoora Repatriation Mental Hospital
Melbourne, Australia
1948–1949
Dr. John Frederick Joseph Cade (1912–1980)
The Man
John Cade was a quietly brilliant Australian psychiatrist who had spent years as a Japanese prisoner of war in Changi Prison. His wartime observations that severely stressed prisoners developed behavioral changes led him to hypothesize that mania might be caused by a toxic substance circulating in the body.
The Experiment
Working in a makeshift laboratory — a converted pantry — with almost no funding, Cade began injecting guinea pigs with urine from manic patients, hypothesizing it contained a manic-producing toxin.
Experimental Logic (Cade's reasoning):
─────────────────────────────────────────
Manic patients → produce abnormal urine?
↓
Inject guinea pigs with manic urine
↓
Do they become "manic"?
↓
Identify the toxic compound
↓
Find an antidote
He identified urea and uric acid as potentially active components. To make uric acid soluble enough to inject, he used lithium urate — choosing lithium pragmatically, not therapeutically.
The Accidental Discovery
“I observed that the guinea pigs became lethargic and unresponsive to stimuli before succumbing to the lethal dose”
Cade noticed that lithium made guinea pigs calm and sedated — not just tranquilized, but in a qualitatively different state. They were placid but alert. This was remarkable. He reasoned: if lithium calms excited animals, could it calm excited humans?
The Human Trials (1948)
Cade first tested lithium on himself to establish safety, then administered it to patients:
Patient Zero: W.B.
- 51-year-old man
- Chronic hypomanic excitement for 5 years
- Institutionalized, incoherent, destructive
- Given lithium citrate and lithium carbonate orally
- Within days: Dramatically calmed
- Within weeks: Rational, coherent, conversational
- Within months: Discharged — returned to work for the first time in years
Cade treated 10 manic patients — all responded dramatically. He also tested it in schizophrenia and depression with less impressive results, correctly intuiting it was specifically antimanic.
The Publication
September 3, 1949 — Cade published:
“Lithium salts in the treatment of psychotic excitement” Medical Journal of Australia
This paper, published in a relatively obscure journal, with no funding, no randomized trial, no institutional support, would eventually be recognized as one of the most important papers in the history of psychiatry.
Tragically, because of the simultaneous lithium chloride toxicity scandal in the USA, Cade’s discovery was largely ignored by American psychiatry for nearly 20 years.
CHAPTER 6: MOGENS SCHOU AND SCIENTIFIC VALIDATION (1950s–1960s)
The Man Who Made the World Listen
Risskov Psychiatric Hospital
Aarhus, Denmark
Dr. Mogens Schou (1918–2005)
Schou was perhaps the most important figure in establishing lithium as a legitimate treatment. His personal motivation was profound — his brother suffered from bipolar disorder and was transformed by lithium.
Schou’s Contributions:
1954 — Conducted the first controlled trial of lithium in mania, confirming Cade’s findings with scientific rigor
Key challenges he overcame:
Scientific Resistance:
├── Eliot Slater (UK) argued lithium trials were unethical and results invalid
├── American psychiatry dismissed findings due to 1949 toxicity scandal
├── Psychoanalytic establishment saw no role for "chemical" treatments
└── Pharmaceutical industry had NO interest (lithium was unpatentable —
it's a naturally occurring element)
Schou’s landmark contributions:
- Established therapeutic blood level monitoring (0.6–1.2 mEq/L) — the innovation that made lithium safe
- Demonstrated lithium’s prophylactic effect — not just treating acute mania but preventing future episodes
- Coined and validated the concept of mood stabilization
- Published prolifically throughout the 1950s–60s, slowly shifting European consensus
CHAPTER 7: FDA APPROVAL & GLOBAL ACCEPTANCE (1970)
America’s Long Resistance Ends
The USA lagged dramatically behind Europe and Australia:
Timeline of International Acceptance:
─────────────────────────────────────────────────────
1949 → Cade's discovery (Australia)
1954 → Controlled trials (Denmark/Europe)
1960s → Routine use across Europe and UK
1970 → FDA approval (USA) — 21 years after discovery!
Why 21 years?
- In 1949, the toxicity scandal created deep institutional resistance
- Psychoanalytic dominance in American psychiatry devalued biological treatments
- No pharmaceutical sponsor to fund trials (lithium is unpatentable)
- The FDA required rigorous safety data that took decades to compile
FDA Approval, 1970:
- Approved for acute mania initially
- Later extended to maintenance/prophylaxis of bipolar disorder
- Required serum level monitoring as a condition of use
CHAPTER 8: THE GOLDEN AGE OF LITHIUM (1970s–1990s)
Lithium at Its Peak
During this era, lithium was:
Clinical Status: GOLD STANDARD
├── First-line for acute mania
├── Gold standard for bipolar prophylaxis
├── Explored in unipolar depression augmentation
├── Investigated for suicidality reduction
└── Symbol of biological psychiatry's triumph
Key clinical insights consolidated during this era:
| Finding | Significance |
|---|---|
| Suicide reduction | Suggested a direct biological mechanism |
| Neuroprotective effects | Increased gray matter volume, BDNF upregulation, GSK-3β inhibition |
| Anti-kindling effect | Prevented episode sensitization over time |
| Augmentation in depression | Highly effective strategy for TRD |
| Antisuicidal effect independent of mood | Suggested direct biological mechanism |
Schou received the Lasker Award — often considered the American Nobel — in 1987 for his work establishing lithium’s prophylactic role.
CHAPTER 9: THE DECLINE — HOW AND WHY LITHIUM FELL (1990s–Present)
A Convergence of Forces Against Lithium
The decline of lithium prescribing is one of the most complex and controversial stories in modern psychiatry, involving science, commerce, culture, and regulatory dynamics.
9A. The Pharmaceutical Industry Factor
THE CORE PROBLEM FOR INDUSTRY:
Lithium = Naturally occurring element = UNPATENTABLE
↓
No proprietary drug = No profit motive
↓
No industry-funded trials = No marketing = No promotion
↓
No detailing to physicians = Reduced prescribing
The patented competitors arrived:
| Drug | Approval for Bipolar | Marketing Machine |
|---|---|---|
| Valproate (Depakote) | 1995 (mania) | Massive Abbott Laboratories campaign |
| Olanzapine (Zyprexa) | 2000 (mania/maintenance) | Enormous Eli Lilly investment |
| Quetiapine (Seroquel) | 2004 (mania/depression/maintenance) | AstraZeneca’s most profitable drug |
| Lamotrigine (Lamictal) | 2003 (maintenance) | GSK promotion |
| Aripiprazole, Risperidone | Various | Extensive marketing |
Each of these drugs arrived with pharmaceutical representatives, CME funding, conference symposia, journal supplements, and key opinion leader networks — none of which lithium could ever have.
9B. The Tolerability Narrative
A powerful clinical narrative, developed — not entirely inaccurate — that lithium was difficult to use and poorly tolerated:
Lithium's Real Adverse Effects:
├── Tremor (fine resting tremor, dose-related)
├── Polyuria/polydipsia (nephrogenic diabetes insipidus)
├── Weight gain
├── Cognitive dulling ("lithium fog")
├── Hypothyroidism (long-term)
├── Renal impairment (long-term, especially with toxicity)
├── Teratogenicity concerns (Ebstein's anomaly — later found overstated)
└── Narrow therapeutic index requiring blood monitoring
However — critical nuance:
- Many side effects are dose-dependent and manageable
- Newer competitors had their own serious side effects (metabolic syndrome, tardive dyskinesia, valproate teratogenicity — far worse than lithium’s)
- The monitoring requirement was reframed as a burden rather than a safety feature
- Renal toxicity risk, while real, was significantly overstated in clinical teaching relative to evidence
9C. The Ebstein’s Anomaly Scare
- Early case reports suggested lithium in the first trimester caused Ebstein’s anomaly (tricuspid valve malformation) at rates far higher than the background
- Pregnancy was considered a strong contraindication
- Later, large registry studies showed the absolute risk was very small (0.1% vs 0.05% background)
- But the teaching had already propagated — generations of psychiatrists trained to avoid lithium in women of reproductive age
- This disproportionately reduced lithium prescribing in young women — a core bipolar demographic
9D. Diagnostic Expansion & Prescribing Drift
DSM Evolution Impact on Lithium:
──────────────────────────────────────────────────────
DSM-III (1980): Narrower bipolar definition
↓
DSM-IV (1994): Bipolar II, cyclothymia expanded
↓
DSM-5 (2013): Broader spectrum recognized
↓
More patients diagnosed = More prescribers unfamiliar with lithium
↓
Default to "easier," promoted alternatives
- As bipolar diagnosis expanded, many new prescribers defaulted to newer, heavily marketed agents
- Psychiatry residency training shifted — many trainees had limited supervised lithium experience
- Primary care physicians who increasingly manage bipolar disorder almost never use lithium
9E. Prescribing Data — The Numbers
USA Prescribing Trends (approximate):
─────────────────────────────────────────
1970s: Lithium = ~80–90% of mood stabilizer prescriptions
1990s: Lithium = ~50% (valproate rising)
2000s: Lithium = ~30% (atypical antipsychotics surging)
2010s: Lithium = ~15–20%
2020s: Lithium = ~10–15% of bipolar maintenance prescriptions
Studies from the UK, USA, and Australia consistently show a steep secular decline in lithium prescribing from the 1990s onward, with atypical antipsychotics (especially quetiapine) becoming the de facto default.
9F. What Was Lost — The Evidence Lithium Still Outperforms
The irony of lithium’s decline is that the evidence base continued to strengthen in its favor even as prescribing fell:
| Outcome | Lithium Evidence |
|---|---|
| Suicide prevention | Superior to ALL alternatives — only drug with robust evidence for reducing suicide and suicide attempts in bipolar disorder |
| All-cause mortality | Lithium reduces mortality beyond suicide prevention |
| Neuroprotection | Gray matter preservation; possible dementia protection |
| Long-term relapse prevention | Comparable or superior to valproate and quetiapine in head-to-head trials |
| Augmentation in TRD | Strong evidence; underused |
| TEAS (treatment-emergent affective switch) | Lower switch rate than antidepressants alone |
The BALANCE trial (2010, Lancet) — the largest lithium maintenance trial ever — showed lithium superior to valproate for preventing relapse in bipolar I. Prescribing continued to decline regardless.
CHAPTER 10: THE RENAISSANCE? — LITHIUM TODAY
Growing Voices for Reconsideration
A significant counter-movement is emerging:
Arguments for Lithium Revival:
├── Suicide reduction evidence is unique and irreplaceable
├── Neuroprotective properties increasingly validated
├── Long-term safety with proper monitoring is acceptable
├── Atypical antipsychotics' metabolic burden increasingly recognized
├── Pharmacoeconomic advantage (lithium is extremely cheap)
├── Possible role in Alzheimer's disease (trials ongoing)
└── Low-dose lithium in drinking water — population-level suicide reduction data
Novel research frontiers:
- Alzheimer’s prevention — observational studies and early trials suggesting lithium slows cognitive decline
- Low-dose lithium — microdose studies exploring neuroproliferative effects without toxicity burden
- Epidemiological data — regions with naturally higher lithium in drinking water consistently show lower suicide rates
THE FULL LITHIUM TIMELINE
1817 ────── Element discovered (Arfwedson, Sweden)
1843 ────── Lithium prescribed for gout
1871 ────── First psychiatric use, lithium bromide (Hammond, USA)
1880s ───── Peak of uric acid theory; lithium widely used
1896 ────── Uric acid theory collapses; lithium abandoned
1940s ───── Lithium chloride used as salt substitute
1949 Feb ── Lithium chloride deaths; FDA warning (USA)
1949 Sep ── Cade's landmark paper (Australia)
1954 ────── Schou's first controlled trial (Denmark)
1960s ───── Routine use in Europe; ignored in USA
1970 ────── FDA approval (USA) — 21 years after discovery
1970s-80s ─ Golden age; gold standard for bipolar
1987 ────── Schou awarded Lasker Award
1990s ───── Valproate approved; pharmaceutical competition begins
2000s ───── Atypical antipsychotics surge; lithium decline accelerates
2010 ────── BALANCE trial proves lithium superiority; ignored commercially
2020s ───── ~10–15% of bipolar maintenance prescriptions
Future? ─── Alzheimer's trials; low-dose research; possible renaissance
Summary Reflection
Lithium’s story is one of the most human stories in medicine — accidental discovery by a lone researcher in a pantry, nearly killed by a commercial disaster, resurrected by a man motivated by his brother’s suffering, proven superior by evidence, and then abandoned not because of science but because of commerce, training gaps, and the unstoppable machinery of pharmaceutical marketing. Its unpatentable nature — the very thing that makes it universally affordable — is the precise reason it was left behind.
Would you like to explore the neurobiology of lithium’s mechanism of action, the evidence on lithium and suicide prevention in detail, or the emerging Alzheimer’s research?
